Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals.
The team hope the compound –developed after 10 years of painstaking research will be trialled on humans within three to four years.
The drug- which works by targeting Mycobacterium tuberculosis’ defences rather than the bacteria itself – can also take out its increasingly commonly antibiotic resistant strains.
The research funded by the Medical Research Council – is published today in the Journal of Medicinal Chemistry.
Although a vaccine for TB was developed 100 years ago, one in three people across the world are thought to be infected with the infectious disease.
About 1.7 million die from the bug each year worldwide and 7.3 million people were diagnosed and treated in 2018, up from the 6.3 million in 2016.
It is most common in Africa, India and China, but on the rise in the UK with London often described as the TB capital of Europe.
Patients are forced to take a cocktail of strong antibiotics over 6 to 8 months, often enduring unpleasant side effects with a 20% risk that the disease will return.
But now The University of Manchester team’s discovery has been proven effective in guinea pigs at Rutgers University in the United States.
The animals with acute and chronic TB infection were treated with the compound, which was discovered after investigating dozens of other derivatives and compounds thought to have similar properties.
Professor Lydia Tabernero is the project leader. She said: “The fact that the animal studies showed our compound, which doesn’t kill the bacteria directly, resulted in a significant reduction in the bacterial burden is remarkable.
“For more than 60 years, the only weapon doctors have been able to use against TB is antibiotics. But resistance is becoming an increasingly worrying problem and the prolonged treatment is difficult and distressing for patients.
“And with current treatments, there’s no guarantee the disease will be eliminated: antibiotics do not clear the infection and the risk of being infected with drug-resistant bacteria is very high.
“But by disabling this clandestine bacteria’s defences we’re thrilled to find a way that enhances the chances of the body’s immune system to do its job, and thus eliminate the pathogen.”
Mycobacterium Tuberculosis secretes molecules called Virulence Factors – the cell’s secret weapon -which block out the immune response to the infection, making it difficult to treat.
The team identified one Virulence Factor called MptpB as a suitable target, which when blocked allows white blood cells to kill Mycobacterium Tuberculosis in a more efficient way
Professor Tabernero added: “The great thing about MptpB is that there’s nothing similar in humans – so our compound which blocks it is not toxic to the human cells.
“Because the bacteria hasn’t been threatened directly, it is less likely to develop resistance against this new agent, and this will be a major advantage over current antibiotics, for which bacteria had already become resistant.
“TB is an amazingly difficult disease to treat so we feel this is a significant breakthrough.
”The next stage of our research is to optimise further the chemical compound, but we hope clinical trials are up to four years away.”
Learn more: Scientists develop new drug treatment for TB
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- New imaging method could cut tuberculosis treatment timeon February 28, 2020 at 12:41 am
A new monitoring approach could help improve treatment of patients with tuberculosis, researchers say. TB is an infectious disease that primarily affects the lungs. Treatment involves multiple pills ...
- Vendor employee at Microsoft diagnosed with tuberculosison February 27, 2020 at 7:30 pm
A vendor at a Microsoft facility in Redmond was recently diagnosed with active tuberculosis (TB), according to officials with Public Health - Seattle & King County. The person had contact with nearly ...
- Worker Diagnosed With Active Tuberculosis At Microsoft Facilityon February 27, 2020 at 5:57 pm
Public health employees are working to perform precautionary tests on 150 employees after a vendor was diagnosed with active TB.
- UPMC Says No To Identifying Tuberculosis-Infected Nurseon February 27, 2020 at 3:42 pm
Law360 (February 27, 2020, 6:17 PM EST) -- Turning over the name and medical records of a former University of Pittsburgh Medical Center employee who potentially exposed thousands of patients and ...
- BRIEF-Pds Biotechnology Announces Commencement Of Work Under A Pre-Clinical Tie-up With Farmacore Biotechnology For Tuberculosison February 27, 2020 at 8:15 am
PDS Biotechnology Corp: * PDS BIOTECHNOLOGY ANNOUNCES COMMENCEMENT OF WORK UNDER A PRE-CLINICAL COLLABORATION WITH FARMACORE BIOTECHNOLOGY FOR TUBERCULOSIS * PDS BIOTECHNOLOGY - PDS BIOTECH WILL UNDER ...
- How to identify tuberculosis earliest?on February 27, 2020 at 7:35 am
Tuberculosis is a contagious disease, so many people wonder if they have any signs or symptoms to know whether they have TB, or what diagnostic tests are needed to know their TB status.
- BRIEF-Gsk Says Collaboration Launched To Develop Treatment Regimens For Tuberculosison February 27, 2020 at 5:25 am
GlaxoSmithKline PLC: * GSK SAYS GLOBAL COLLABORATION LAUNCHED TO DEVELOP TREATMENT REGIMENS FOR TUBERCULOSIS * GSK-COLLABORATION AIMS TO ACCELERATE DEVELOPMENT OF NOVEL “PAN-TB” DRUG REGIMENS FOR TREA ...
- Tuberculosis Diagnostics and Treatment Market 2020 – Global Industry Analysis, Size, Share, Trends, Growth, Opportunities and Forecast 2024on February 25, 2020 at 10:35 pm
Tuberculosis Diagnostics and Treatment Market 2020 reports contains Industry Analysis, Market Share, Size with Sales, Price, Revenue, Gross Margin, Competitor analysis and Forecast to 2024.
- Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosison February 25, 2020 at 8:55 am
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is a global health problem. At present, prior exposure to Mtb can be determined by blood-based interferon-gamma release assay (IGRA), but ...
via Bing News